
ADMA Biologics Faces Class Action Lawsuit Over Revenue Allegations
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, are being urged to contact Kessler Topaz Meltzer & Check, LLP. A securities fraud class action lawsuit, filed in the U.S. District Court for the District of New Jersey, claims the company misled shareholders regarding its internal financial controls.
























